DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21165/S-017
NDA 21300/S-014
NDA 21312/S-015
NDA 21563/S-003

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corporation
126 E. Lincoln Avenue
Mailstop RY33-204
Rahway, NJ 07065-0900

Attention: Scott Greenfeder, Ph.D.
Director and Liaison, Global Regulatory Affairs

Dear Dr. Greenfeder:

Please refer to your Supplemental New Drug Application (sNDA) dated October 23, 2013, received October 23 and October 24, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Clarinex (desloratadine) Tablets, Clarinex (desloratadine) Oral Solution, and Clarinex (desloratadine) Reditabs.

We acknowledge receipt of your amendments dated October 24, 2013 (NDA 21312/S-015), and January 9, February 26, April 1 and 22, 2014.

These "Changes Being Effected" supplemental new drug applications provide for the addition of the language related to "movement disorders" into the ADVERSE REACTION, Section 6.2 - Post-Marketing Experience section and the inclusion of the Reditab formulation in the package insert.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient information leaflet), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your applications, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Philantha Bowen, Senior Regulatory Project Management Officer, at (301) 796-2466.

Sincerely,

{See appended electronic signature page}

Sally Seymour, M.D.
Deputy Director for Safety
Division Pulmonary, Allergy, and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SALLY M SEYMOUR
04/23/2014